Novo Nordisk A/S (NVO)
Stock Price:
$65.77 USD
-0.57 (-0.86%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
117.93B |
| Revenue (ttm) |
20.13B |
| Net Income (ttm) |
6.59B |
| Shares Out |
2.33B |
| EPS (ttm) |
2.46 |
| PE Ratio |
26.74 |
| Forward PE |
22.88 |
| Dividend |
$1.57 |
| Dividend Yield |
2.39% |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$65.77 |
| Previous Close |
$66.34 |
| Change ($) |
-0.57 |
| Change (%) |
-0.86% |
| Day's Open |
65.96 |
| Day's Range |
65.57 - 66.22 |
| Day's Volume |
499,587 |
| 52-Week Range |
48.60 - 68.96 |
More Stats
| Market Cap |
117.93B |
| Enterprise Value |
114.64B |
| Earnings Date (est) |
Oct 30, 2020 |
| Ex-Dividend Date |
Aug 14, 2020 |
| Shares Outstanding |
2.33B |
| Float |
1.66B |
| EPS (basic) |
n/a |
| EPS (diluted) |
2.46 |
| FCF / Share |
3.31 |
| Dividend |
$1.57 |
| Dividend Yield |
2.39% |
| Earnings Yield |
3.74% |
| FCF Yield |
6.62% |
| Payout Ratio |
n/a |
| Shares Short |
2.79M |
| Short Ratio |
2.71 |
| Short % of Float |
n/a |
| Beta |
0.39 |
| PE Ratio |
26.74 |
| Forward PE |
22.88 |
| P/FCF Ratio |
15.11 |
| PS Ratio |
5.86 |
| PB Ratio |
15.74 |
| Revenue |
20.13B |
| Operating Income |
8.74B |
| Net Income |
6.59B |
| Free Cash Flow |
7.81B |
| Net Cash |
3.30B |
| Net Cash / Share |
1.84 |
| Gross Margin |
83.67% |
| Operating Margin |
43.40% |
| Profit Margin |
32.70% |
| FCF Margin |
38.78% |
| ROA |
27.51% |
| ROE |
73.24% |
| ROIC |
n/a |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (29)
| Buy |
13 |
| Overweight |
2 |
| Hold |
10 |
| Underweight |
1 |
| Sell |
3 |
Analyst Consensus: Overweight
Price Target
$70.82*
(7.68% upside)
Low
46.4
Current: $65.77
High
83.5
Target: 70.82
*Average 12-month USD price target from 25 stock analysts.
Financial Performance
Financial numbers in millions DKK.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 122,021 | 111,831 | 111,696 | 111,780 | 107,927 | 88,806 |
| Revenue Growth | 9.11% | 0.12% | -0.08% | 3.57% | 21.53% | - |
| Gross Profit | 101,933 | 94,214 | 94,064 | 94,597 | 91,739 | 74,244 |
| Operating Income | 52,483 | 47,248 | 48,967 | 48,432 | 49,444 | 32,952 |
| Net Income | 38,951 | 38,628 | 38,130 | 37,925 | 34,860 | 26,481 |
| Shares Outstanding | 2,450 | 2,500 | 2,550 | 2,600 | 2,597 | - |
| Earnings Per Share | 16.38 | 15.93 | 15.39 | 14.96 | 13.52 | 10.07 |
| EPS Growth | 2.82% | 3.51% | 2.87% | 10.65% | 34.26% | - |
| Dividend Per Share | 1.02 | 1.05 | 1.15 | 1.41 | 0.56 | 0.84 |
| Dividend Growth | -2.87% | -8.81% | -18.78% | 154.23% | -33.85% | - |
| Operating Cash Flow | 46,782 | 44,616 | 41,168 | 48,314 | 38,287 | 31,692 |
| Capital Expenditures | -8,928 | -9,623 | -7,617 | -7,061 | -5,209 | -3,986 |
| Free Cash Flow | 37,854 | 34,993 | 33,551 | 41,253 | 33,078 | 27,706 |
| Cash & Equivalents | 15,475 | 15,638 | 18,852 | 20,699 | 20,465 | 15,905 |
| Total Debt | 4,483 | 515 | 1,694 | 229 | 1,073 | 720 |
| Net Cash / Debt | 10,992 | 15,123 | 17,158 | 20,470 | 19,392 | 15,185 |
| Assets | 125,612 | 110,769 | 102,355 | 97,539 | 91,799 | 77,062 |
| Liabilities | 68,019 | 58,930 | 52,540 | 52,270 | 44,830 | 36,768 |
| Book Value | 57,593 | 51,839 | 49,815 | 45,269 | 46,969 | 40,294 |
Numbers in millions DKK, except per-share numbers.
Company Details
| Full Name |
Novo Nordisk A/S |
| Country |
Denmark |
| Employees |
43,526 |
| CEO |
Lars Fruergaard Jørgensen |
Stock Information
| Ticker Symbol |
NVO |
| Stock Exchange |
New York Stock Exchange |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSE: NVO |
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.